This report provides findings from a qualitative analysis of evidence-based and culturally relevant behavioral health practices offered at NNEDLearn, a SAMHSA training, offered from 2011 to 2020. It includes an overview of NNEDLearn, case studies, strategies and lessons learned, and conclusion.

This guide reviews ways that telehealth modalities can be used to provide treatment for serious mental illness and substance use disorders among adults, distills the research into recommendations for practice, and provides examples of how these recommendations can be implemented.

This Advisory is based on TIP 31, Screening and Assessing Adolescents for Substance Use Disorders (SUDs) and TIP 32, Treatment of Adolescents with SUDs. It includes recommendations for engaging adolescents in SUD risk assessment, screening, and treatment.

This report provides evidence-based practices for screening and assessment of adults in the justice system with mental illness, substance use disorders, or both. It discusses the importance of instrument selection for screening and assessment and provides detailed descriptions of recommended instruments.

This manual provides guidelines for the operation of opioid treatment programs. It covers patient assessment, treatment planning, and recovery care. The manual also offers guidance for medication-assisted treatment for methadone and buprenorphine, and overdose and relapse prevention.

This quick guide helps administrators of substance use disorder treatment facilities implement programs and services that address the needs of women living with substance use disorders. It addresses patterns of use and the drug screening and treatment needs of women.

This handbook reviews Medicaid and its role in financing services and treatment for mental illness and substance use disorders. It discusses services included in state Medicaid plans and other factors related to Medicaid, such as reimbursement.

This manual guides counselors in the use of medications to help clients achieve abstinence from alcohol. It describes how the medications work and whom may benefit. It also presents the side effects of three FDA-approved medications: acamprosate, disulfiram, and naltrexone.